PressNovember 28, 2023 Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
PressNovember 28, 2023 Filament Health Signs Non-Binding Term Sheet for Convertible Note in Connection with Planned Business Combination
PressNovember 28, 2023 Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
PressNovember 21, 2023 Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
PressNovember 21, 2023 Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
PressNovember 20, 2023 Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
PressNovember 20, 2023 Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
PressNovember 20, 2023 FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement
PressNovember 16, 2023 Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
PressNovember 16, 2023 Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
PressNovember 16, 2023 PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
PressNovember 16, 2023 US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
PressNovember 16, 2023 Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
PressNovember 16, 2023 Filament Health Announces Third Quarter 2023 Financial Results and Operational Highlights
PressNovember 14, 2023 Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
PressNovember 14, 2023 Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
